Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder (Q38266796)

1 September 2017

1 reference

title

Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder (English)

1 reference

1 September 2017

main subject

autism spectrum disorder

0 references

0 references

1 reference

1 reference

Mariken Dinnissen

1 reference

1 September 2017

Andrea Dietrich

series ordinal

1 reference

1 September 2017

Barbara J van den Hoofdakker

series ordinal

1 reference

1 September 2017

Pieter J Hoekstra

series ordinal

1 reference

1 September 2017

language of work or name

English

0 references

publication date

11 November 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

1 September 2017

published in

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

111-124

1 reference

Prevalence of autism-spectrum conditions: UK school-based population study

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Epidemiology of autism spectrum disorders in adults in the community in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Prevalence of autism spectrum disorders in a total population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Comorbid psychopathology with autism spectrum disorder in children: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Autism spectrum disorders: an overview on diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Intervention for optimal outcome in children and adolescents with a history of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Comparison of behavior analytic and eclectic early interventions for young children with autism after three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Functional analysis of problem behavior: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Use of psychotropic medication in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

The variation of psychopharmacological prescription rates for people with autism spectrum disorder (ASD) in 30 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Psychopharmacological interventions in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

New experimental treatments for core social domain in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Aggression in children and adolescents with ASD: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Discovering risperidone: the LSD model of psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

An open trial of risperidone in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Open trial of risperidone in 24 young children with pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone and adaptive behavior in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Self injurious behavior in autism: clinical aspects and treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A crossover study of risperidone in children, adolescents and adults with mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Deconstructing executive deficits among persons with autism: implications for cognitive neuroscience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Cognitive effects of risperidone in children with autism and irritable behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Developing new pharmacotherapies for autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

The prevalence of obesity in children with autism: a secondary data analysis using nationally representative data from the National Survey of Children's Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Use of functional analysis methodology in the evaluation of medication effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.981151

10.1517/17425255.2015.981151

21 January 2018

Identifiers

DOI

1 reference

release_42hat3jqyvd4vk3xvmeovcfyqu

1 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/42hat3jqyvd4vk3xvmeovcfyqu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference